DISCLAIMER
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.compose your message
message sent
email sent successfully
Trusted Resources: News & Events
Latest announcements and gatherings
Public Meeting on Patient-Focused Drug Development for Chronic Pain
Meeting Information:
On July 9, 2018, FDA is hosting a public meeting on Patient-Focused Drug Development for Chronic Pain. FDA is interested in hearing patients’ perspectives on chronic pain, views on treatment approaches, and challenges or barriers to accessing treatments for chronic pain. FDA is particularly interested in hearing from patients who experience chronic pain.
Date: July 9, 2018
Time: 10:00 a.m. – 4:00 p.m. (registration will begin at 9:00am)
Location:
FDA White Oak Campus
10903 New Hampshire Ave.
Building 31, Room 1503 B & C (Great Room)
Silver Spring, MD 20993
This event has ended.


Related Content
-
news & eventsAlzheimer’s Treatment Memantine Shows Promise in Treating Sickle Cell DiseaseMemantine, a standard treatment for Alzh...
-
videos & visualsMalik was Cured From Sickle Cell Disease (Teaser)https://www.youtube.com/watch?v=RddQ_qvh...
-
education & researchPreoperative blood transfusions for sickle cell diseaseBackground: Sickle cell disease is one ...
-
news & eventsTown Hall Meeting: A policy discussion on the challenges facing the sickle cell communityHemoglobinopathies (Sickle Cell ...
-
news & events
-
news & eventsPhase 1 trial to test under-the-skin injection of sevuparin in sickle cell patientsModus Therapeutics is going to launch ...
-
education & researchCognitive behavioral therapy in patients with sickle cell diseaseIntroduction: Sickle cell disease (SCD) ...
send a message
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Support for this site is provided by

This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.